Kura Oncology, Inc. · NASDAQ:KURA
Kura Oncology — Technical Presentation (July 2026)
10 slides from Kura Oncology's technical presentation, July 2026
Slide 1: Darlifarnib combined with cabozantinib in RCC: Updated phase 1a results from FIT-001
Farnesyl transferase inhibitor (FTI) darlifarnib combined with cabozantinib in renal cell carcinoma (RCC): Updated phase 1a results from FIT-001 Adanma Ayanambakkam1, Yousef Zakharia2, Lee S. Rosen3, Benjamin Garmezy4, Meredith Pelster5, Glenn J. Hanna6, Jason Henry7, Jacob Thomas8, Manish R. Patel9
Slide 2: Darlifarnib Has Potential to Enhance Activity of VEGFR-TKIs in RCC
Darlifarnib Has Potential to Enhance Activity of VEGFR-TKIs in RCC Darlifarnib + cabozantinib mechanism of action in RCC • VEGFR-TKIs are active for advanced RCC but are limited by persistent mTORC1 signaling that promotes tumor growth, angiogenesis, and disease progression1–4 • Outcomes with existi
Slide 3: FIT-001: Phase 1a Trial of Darlifarnib and Cabozantinib in Locally Advanced or Metastatic RCC
FIT-001: Phase 1a Trial of Darlifarnib and Cabozantinib in Locally Advanced or Metastatic RCC Key Eligibility Criteria Phase 1a Dose Escalationa,b • Age ≥18 years Darlifarnib administered orally QD on Days 1–7 and 15–21 plus • Histologically or cytologically confirmed RCC cabozantinib administered o
Slide 4: Baseline Characteristics
Baseline Characteristics All RCC Patients Total n (%) (N=72) Median age, years (range) 67 (24–83) Male 55 (76) • As of May 8, 2026, 72 RCC patients were Race treated with the combination across dose White 54 (75) escalation cohorts Non-Whitea 18 (25) RCC type • 27 patients remained on treatment Clea
Slide 5: Safety and Tolerability of Darlifarnib + Cabozantinib
Safety and Tolerability of Darlifarnib + Cabozantinib All RCC Patients Total (N=72) Related to Related to Total n (%) Any-Grade Grade ≥3 n (%) darlifarnib cabozantinib (N=72) TEAEs (≥30% of all patients) TEAEs, any grade 65 (90) 69 (96) 71 (99) Diarrhea 46 (64) 6 (8) Grade ≥3 42 (58) 41 (57) 55 (76)
Slide 6: ORR and DCR
ORR and DCR Cabozantinib-Naive ccRCCa Cabozantinib 60 mgd Darlifarnib + Cabozantinib Darlifarnib Darlifarnib Darlifarnib 40 mg 3 mg 5 mg 8 mg n (%) [95% CI] (N=6) (n=6) (n=10) (n=12) 2 (33) 2 (33) 5 (50)e 4 (33) ORR (CR+PR) [4.3–77.7] [4.3–77.7] [18.7–81.3] [9.9–65.1] 5 (83) 6 (100) 8 (80) 12 (100)
Slide 7: Duration of Treatment and Clinical Outcomes
Duration of Treatment and Clinical Outcomes Cabozantinib-Naive ccRCC • Durable clinical benefit was observed across all evaluated combination dose levels, with more than half of patients remaining on treatment aMedian follow-up was 9.4 months (95% CI 6.9–12.8); PFS is aggregated across dose levels a
Slide 8: Conclusions
Conclusions CLINICAL • With long-term follow-up, the combination has demonstrated durable and encouraging ACTIVITY antitumor activity in cabozantinib-naive and -exposed patients1, with ORRs of 33%–50% and mPFS of 13 months in cabozantinib-naive patients from the FIT-001 phase 1a study • The combinat
Slide 9: FIT-001: Phase 1b Combination Trial in Cabozantinib-Naive Locally Advanced or Metastatic ccRCC
FIT-001: Phase 1b Combination Trial in Cabozantinib- Naive Locally Advanced or Metastatic ccRCC Dose Optimization to Establish Recommended Phase 3 Dose is Ongoing in Phase 1b Key Eligibility Criteria Phase 1b: Expansion and Dose Optimization in ccRCC • ≥1 prior systemic therapy with IO-based Darlifa
Slide 10: Acknowledgments
Acknowledgments • We would like to thank the patients, their families, and their caregivers, as well as the FIT-001 study investigators and their study teams. • This study was sponsored by Kura Oncology, Inc. • Medical writing support was provided by Shawn Jaramillo, PharmD, of Oxford PharmaGenesis